Blog

Cardinal Health and Vineti announce collaboration to deliver integrated commercial and logistics solutions to cell and gene therapy manufacturers

by Vineti | May 20, 2020

DUBLIN, OHIO and SAN FRANCISCO, CA – May 20, 2020 — Cardinal Health and Vineti Inc. today announced a collaboration to support cell and gene therapy manufacturers with a fully integrated solution that aligns logistics and commercialization services with digital Chain of Identity and Chain of Custody throughout the treatment journey.

Cardinal Health supports the cell and gene therapy market with a robust suite of services that includes end-to-end logistics, regulatory strategy, order-to-cash management and patient access and support services. Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for cell and gene therapies. The Vineti platform delivers digital Chain of Identity and Chain of Custody, providing essential patient safety and regulatory compliance across the value chain.  

Together, Cardinal Health and Vineti will develop best-in-class solutions to support the distribution of transformative, personalized therapies for cancer and other serious diseases.  Specifically, Cardinal Health and Vineti will focus on integrated solutions that enable cell and gene therapy manufacturers to accelerate the commercialization of their products, while delivering a more simple, seamless and secure experience to hospitals and patients, from initial patient enrollment through delivery of the final dose of therapy and beyond.

 “Cell and gene therapies have the most complex supply chain of any pharmaceutical product. As we work with manufacturers to bring these innovative therapies to market, the importance of coordination and control at each step cannot be overstated,” said Joel Wayment, Vice President of Cardinal Health 3PL. “Vineti has developed a market-leading digital platform for tracking Chain of Identity and Chain of Custody. Working collaboratively, we expect to develop the critical rails to help biopharma companies ensure that patients can access these advanced therapies.”

“Vineti’s mission is to industrialize advanced therapies and open up patient access,” said Amy DuRoss, CEO and Co-founder of Vineti. “Cardinal Health’s vast expertise, networks, and resources make them an ideal partner in this transformative endeavor. We’re very honored to work with Cardinal Health and look forward to serving biopharmaceutical innovators, clinicians, and patients together for years to come.”


About Vineti‚Ä®

Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges that patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The company is expanding rapidly, and the Vineti platform will be in use in hundreds of leading medical centers worldwide in 2019, on behalf of multiple biopharmaceutical partners. In 2019, the World Economic Forum selected Vineti as a global Technology Pioneer.

About Cardinal Health 

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products, pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. To help combat prescription drug abuse, the company and its education partners created Generation Rx, a national drug education and awareness program. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks #14 on the Fortune 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter, Cardinal Health on Facebook and connect on LinkedIn at linkedin.com/ company/cardinal-health.

Media:

Cardinal Health: Marcia Frederick | 614-757-9968
marcia.frederick@cardinalhealth.com

Cardinal Investors: Kevin Moran | (614) 757-7942
kevin.moran@cardinalhealth.com 

Vineti: Stacy Henry for Vineti CEO Amy DuRoss
amy@vineti.com

 

Back to Blog